Tokyo Tape
Sign in
← Chiome Bioscience

Half-year report · Q2

4583.TEDINET S100U79O
Period2024-01-01 → 2024-06-30
Filed2024-08-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥264m2024-01-01 → 2024-06-30StandaloneNet sales
Revenue¥682m2023-01-01 → 2023-12-31StandaloneNet sales (5-year summary)
Revenue¥359m2023-01-01 → 2023-06-30StandaloneNet sales
Operating income−¥581m2024-01-01 → 2024-06-30StandaloneOperating income
Operating income−¥659m2023-01-01 → 2023-06-30StandaloneOperating income
Ordinary income−¥563m2024-01-01 → 2024-06-30StandaloneOrdinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥662m2023-01-01 → 2023-06-30StandaloneOrdinary income
Profit before tax−¥562m2024-01-01 → 2024-06-30StandaloneIncome before income taxes
Profit before tax−¥661m2023-01-01 → 2023-06-30StandaloneIncome before income taxes
Net income−¥564m2024-01-01 → 2024-06-30StandaloneProfit loss
Net income−¥1.2bn2023-01-01 → 2023-12-31StandaloneNet income loss (5-year summary)
Net income−¥664m2023-01-01 → 2023-06-30StandaloneProfit loss
Total assets¥1.6bnat 2024-06-30StandaloneAssets
Total assets¥1.8bnat 2023-12-31StandaloneAssets
Total assets¥1.7bnat 2023-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥487mat 2024-06-30StandaloneLiabilities
Total liabilities¥594mat 2023-12-31StandaloneLiabilities
Net assets / equity¥1.1bnat 2024-06-30StandaloneNet assets
Net assets / equity¥1.2bnat 2023-12-31StandaloneNet assets
Net assets / equity¥1.1bnat 2023-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.1bnat 2024-06-30StandaloneCash and deposits
Cash and deposits¥1.3bnat 2023-12-31StandaloneCash and deposits
Cash & equivalents¥1.1bnat 2024-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.3bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2023-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.7bnat 2022-12-31dStandaloneCash and cash equivalents
Operating cash flow−¥677m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥595m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow¥173,0002023-01-01 → 2023-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥82,0002023-01-01 → 2023-06-30StandaloneNet cash provided by used in investment activities
Financing cash flow¥455m2024-01-01 → 2024-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥667m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥113m2023-01-01 → 2023-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-10.212024-01-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-24.622023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-13.72023-01-01 → 2023-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio68.0%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio65.1%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio67.2%at 2023-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued56,387,000at 2024-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued52,640,200at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued48,503,800at 2023-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥269m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2024-01-01 → 2024-06-30−¥447m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2024-01-01 → 2024-06-30¥264m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2024-01-01 → 2024-06-30¥135m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-06-30¥264m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-06-30−¥312m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥266m
jpcrp040300-q2r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-06-30−¥602m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-06-30¥359m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-06-30¥359m
jpcrp040300-q2r_E26096-000Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-06-30¥209m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-06-30¥359m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-06-30¥359m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-06-30−¥393m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 447
ItemContextValueUnit
Deposits receivedCurrentQuarterInstant_NonConsolidatedMember8187000JPY
Provision for bonusesPrior1YearInstant_NonConsolidatedMember6730000JPY
Provision for bonusesCurrentQuarterInstant_NonConsolidatedMember－JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember539038000JPY
Current liabilitiesCurrentQuarterInstant_NonConsolidatedMember432001000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember54692000JPY
Asset retirement obligations nclCurrentQuarterInstant_NonConsolidatedMember54906000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember54692000JPY
Noncurrent liabilitiesCurrentQuarterInstant_NonConsolidatedMember54906000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember593731000JPY
LiabilitiesCurrentQuarterInstant_NonConsolidatedMember486908000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember2388422000JPY
Capital stockCurrentQuarterInstant_NonConsolidatedMember341497000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember3988202000JPY
Capital surplusCurrentQuarterInstant_NonConsolidatedMember1281771000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-5236350000JPY
Retained earningsCurrentQuarterInstant_NonConsolidatedMember-563958000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-292000JPY
Treasury stockCurrentQuarterInstant_NonConsolidatedMember-292000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember1139981000JPY
Shareholders equityCurrentQuarterInstant_NonConsolidatedMember1059018000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember17741000JPY
Subscription rights to sharesCurrentQuarterInstant_NonConsolidatedMember11513000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1157723000JPY
Net assetsCurrentQuarterInstant_NonConsolidatedMember1070531000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember1751454000JPY
Liabilities and net assetsCurrentQuarterInstant_NonConsolidatedMember1557439000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember358889000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember263728000JPY
Cost of salesPrior1YTDDuration_NonConsolidatedMember150211000JPY
Cost of salesCurrentYTDDuration_NonConsolidatedMember128970000JPY
Gross profitPrior1YTDDuration_NonConsolidatedMember208677000JPY
Gross profitCurrentYTDDuration_NonConsolidatedMember134758000JPY
Research and development expenses sgaPrior1YTDDuration_NonConsolidatedMember601900000JPY
Research and development expenses sgaCurrentYTDDuration_NonConsolidatedMember446817000JPY
Other sgaPrior1YTDDuration_NonConsolidatedMember266026000JPY
Other sgaCurrentYTDDuration_NonConsolidatedMember269077000JPY
Selling general and administrative expensesPrior1YTDDuration_NonConsolidatedMember867926000JPY
Selling general and administrative expensesCurrentYTDDuration_NonConsolidatedMember715894000JPY
Operating incomePrior1YTDDuration_NonConsolidatedMember-659249000JPY
Operating incomeCurrentYTDDuration_NonConsolidatedMember-581136000JPY
Interest income noiPrior1YTDDuration_NonConsolidatedMember10000JPY
Interest income noiCurrentYTDDuration_NonConsolidatedMember20000JPY
Foreign exchange gains noiPrior1YTDDuration_NonConsolidatedMember－JPY
Foreign exchange gains noiCurrentYTDDuration_NonConsolidatedMember519000JPY
Subsidy income noiPrior1YTDDuration_NonConsolidatedMember－JPY
Subsidy income noiCurrentYTDDuration_NonConsolidatedMember19738000JPY
Other noiPrior1YTDDuration_NonConsolidatedMember414000JPY
Other noiCurrentYTDDuration_NonConsolidatedMember798000JPY
Non operating incomePrior1YTDDuration_NonConsolidatedMember424000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-06-30pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-06-30pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-06-30pass